JP2002502844A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2002502844A5 JP2002502844A5 JP2000530502A JP2000530502A JP2002502844A5 JP 2002502844 A5 JP2002502844 A5 JP 2002502844A5 JP 2000530502 A JP2000530502 A JP 2000530502A JP 2000530502 A JP2000530502 A JP 2000530502A JP 2002502844 A5 JP2002502844 A5 JP 2002502844A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- alkyl
- substituted
- alkoxycarbonyl
- carboxy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- -1 piperazino group Chemical group 0.000 description 73
- 125000000217 alkyl group Chemical group 0.000 description 56
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 34
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 31
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 description 30
- 150000001875 compounds Chemical class 0.000 description 29
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 28
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 25
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 20
- 125000003739 carbamimidoyl group Chemical group C(N)(=N)* 0.000 description 17
- 125000006698 (C1-C3) dialkylamino group Chemical group 0.000 description 15
- 150000003839 salts Chemical class 0.000 description 15
- 229910052757 nitrogen Inorganic materials 0.000 description 14
- 125000004433 nitrogen atom Chemical group N* 0.000 description 14
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 13
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 12
- 125000002112 pyrrolidino group Chemical group [*]N1C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 12
- 125000005493 quinolyl group Chemical group 0.000 description 10
- 125000003277 amino group Chemical group 0.000 description 9
- 125000004432 carbon atom Chemical group C* 0.000 description 9
- 125000004093 cyano group Chemical group *C#N 0.000 description 9
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 9
- 125000005956 isoquinolyl group Chemical group 0.000 description 9
- 125000001624 naphthyl group Chemical group 0.000 description 9
- 125000004076 pyridyl group Chemical group 0.000 description 9
- 229910052717 sulfur Inorganic materials 0.000 description 9
- 125000004434 sulfur atom Chemical group 0.000 description 9
- 125000003545 alkoxy group Chemical group 0.000 description 8
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 8
- 125000005328 phosphinyl group Chemical group [PH2](=O)* 0.000 description 8
- 125000006705 (C5-C7) cycloalkyl group Chemical group 0.000 description 7
- 125000002373 5 membered heterocyclic group Chemical group 0.000 description 7
- 125000005605 benzo group Chemical group 0.000 description 7
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 7
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 7
- 125000004430 oxygen atom Chemical group O* 0.000 description 7
- 125000003831 tetrazolyl group Chemical group 0.000 description 7
- 125000006576 di-(C1-C3-alkyl)-aminocarbonyl group Chemical group 0.000 description 6
- 125000002883 imidazolyl group Chemical group 0.000 description 6
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 6
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 6
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- 125000002252 acyl group Chemical group 0.000 description 5
- 125000005079 alkoxycarbonylmethyl group Chemical group 0.000 description 5
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 5
- 125000006518 morpholino carbonyl group Chemical group [H]C1([H])OC([H])([H])C([H])([H])N(C(*)=O)C1([H])[H] 0.000 description 5
- 125000003170 phenylsulfonyl group Chemical group C1(=CC=CC=C1)S(=O)(=O)* 0.000 description 5
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 5
- 125000006563 (C1-3) alkylaminocarbonyl group Chemical group 0.000 description 4
- 125000006559 (C1-C3) alkylamino group Chemical group 0.000 description 4
- 125000004457 alkyl amino carbonyl group Chemical group 0.000 description 4
- 229910052801 chlorine Inorganic materials 0.000 description 4
- 125000000753 cycloalkyl group Chemical group 0.000 description 4
- 125000002993 cycloalkylene group Chemical group 0.000 description 4
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 4
- 229910052731 fluorine Inorganic materials 0.000 description 4
- 125000001841 imino group Chemical group [H]N=* 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 125000001424 substituent group Chemical group 0.000 description 4
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 4
- 125000003282 alkyl amino group Chemical group 0.000 description 3
- 125000002619 bicyclic group Chemical group 0.000 description 3
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 3
- 125000006639 cyclohexyl carbonyl group Chemical group 0.000 description 3
- 229910052739 hydrogen Inorganic materials 0.000 description 3
- 239000001257 hydrogen Substances 0.000 description 3
- 230000007062 hydrolysis Effects 0.000 description 3
- 238000006460 hydrolysis reaction Methods 0.000 description 3
- 230000000269 nucleophilic effect Effects 0.000 description 3
- 125000003226 pyrazolyl group Chemical group 0.000 description 3
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 2
- 125000006555 (C3-C5) cycloalkyl group Chemical group 0.000 description 2
- 125000004173 1-benzimidazolyl group Chemical group [H]C1=NC2=C([H])C([H])=C([H])C([H])=C2N1* 0.000 description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 2
- 108090000190 Thrombin Proteins 0.000 description 2
- 125000004466 alkoxycarbonylamino group Chemical group 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- 229910052794 bromium Inorganic materials 0.000 description 2
- 150000001721 carbon Chemical group 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 238000009903 catalytic hydrogenation reaction Methods 0.000 description 2
- 239000000460 chlorine Substances 0.000 description 2
- 125000001309 chloro group Chemical group Cl* 0.000 description 2
- 125000005167 cycloalkylaminocarbonyl group Chemical group 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 239000011737 fluorine Substances 0.000 description 2
- 125000001153 fluoro group Chemical group F* 0.000 description 2
- 238000007327 hydrogenolysis reaction Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 description 2
- 125000004458 methylaminocarbonyl group Chemical group [H]N(C(*)=O)C([H])([H])[H] 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 238000005979 thermal decomposition reaction Methods 0.000 description 2
- 229960004072 thrombin Drugs 0.000 description 2
- 125000001140 1,4-phenylene group Chemical group [H]C1=C([H])C([*:2])=C([H])C([H])=C1[*:1] 0.000 description 1
- SAMMRXPDTIIEMS-UHFFFAOYSA-N 2-[[2-[(4-carbamimidoylphenyl)methyl]-1-methylbenzimidazol-5-yl]-quinolin-8-ylsulfonylamino]acetic acid Chemical compound N=1C2=CC(N(CC(O)=O)S(=O)(=O)C=3C4=NC=CC=C4C=CC=3)=CC=C2N(C)C=1CC1=CC=C(C(N)=N)C=C1 SAMMRXPDTIIEMS-UHFFFAOYSA-N 0.000 description 1
- XGRGRMFILCCAMJ-UHFFFAOYSA-N 2-[[2-[[2-[(4-carbamimidoylphenyl)methyl]-1-methylbenzimidazol-5-yl]-quinolin-8-ylsulfonylamino]-2-oxoethyl]amino]acetic acid Chemical compound N=1C2=CC(N(C(=O)CNCC(O)=O)S(=O)(=O)C=3C4=NC=CC=C4C=CC=3)=CC=C2N(C)C=1CC1=CC=C(C(N)=N)C=C1 XGRGRMFILCCAMJ-UHFFFAOYSA-N 0.000 description 1
- UBGVJTGBDCGIFL-UHFFFAOYSA-N 2-[[5-[benzenesulfonyl-[2-(diethylamino)ethyl]amino]-2-[(4-carbamimidoylphenyl)methyl]-4-methylbenzimidazole-1-carbonyl]amino]acetic acid Chemical compound C=1C=CC=CC=1S(=O)(=O)N(CCN(CC)CC)C(C(=C1N=2)C)=CC=C1N(C(=O)NCC(O)=O)C=2CC1=CC=C(C(N)=N)C=C1 UBGVJTGBDCGIFL-UHFFFAOYSA-N 0.000 description 1
- DVXBYTXVYTUSLX-UHFFFAOYSA-N 4-[(1-methyl-5-pyrrolidin-1-ylsulfonylbenzimidazol-2-yl)methyl]benzenecarboximidamide Chemical compound N=1C2=CC(S(=O)(=O)N3CCCC3)=CC=C2N(C)C=1CC1=CC=C(C(N)=N)C=C1 DVXBYTXVYTUSLX-UHFFFAOYSA-N 0.000 description 1
- VTDOZSUVQUKQHR-UHFFFAOYSA-N 4-[[2-[(4-carbamimidoylphenyl)methyl]-1-methylbenzimidazol-5-yl]-cyclopentylamino]-4-oxobutanoic acid Chemical compound N=1C2=CC(N(C3CCCC3)C(=O)CCC(O)=O)=CC=C2N(C)C=1CC1=CC=C(C(N)=N)C=C1 VTDOZSUVQUKQHR-UHFFFAOYSA-N 0.000 description 1
- QUYSOYJNGMHQDQ-UHFFFAOYSA-N 4-[[4-cyclopropyl-1-methyl-5-(pyrrolidine-1-carbonyl)benzimidazol-2-yl]methyl]benzenecarboximidamide Chemical compound N=1C2=C(C3CC3)C(C(=O)N3CCCC3)=CC=C2N(C)C=1CC1=CC=C(C(N)=N)C=C1 QUYSOYJNGMHQDQ-UHFFFAOYSA-N 0.000 description 1
- HCZOYKGCPREUFP-UHFFFAOYSA-N 4-[[5-[benzenesulfonyl-[2-(dimethylamino)ethyl]amino]-1-benzylbenzimidazol-2-yl]methyl]benzenecarboximidamide Chemical compound C=1C=CC=CC=1S(=O)(=O)N(CCN(C)C)C(C=C1N=C2CC=3C=CC(=CC=3)C(N)=N)=CC=C1N2CC1=CC=CC=C1 HCZOYKGCPREUFP-UHFFFAOYSA-N 0.000 description 1
- QEERHKYTEJZHPM-UHFFFAOYSA-N 4-[[5-[cyclopentyl(methylsulfonyl)amino]-1-methylbenzimidazol-2-yl]methyl]benzenecarboximidamide Chemical compound N=1C2=CC(N(C3CCCC3)S(C)(=O)=O)=CC=C2N(C)C=1CC1=CC=C(C(N)=N)C=C1 QEERHKYTEJZHPM-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 0 CC(*)(C*(C1)=N)/C=C/C2=C1*=C(PPN=C)I1C2C1 Chemical compound CC(*)(C*(C1)=N)/C=C/C2=C1*=C(PPN=C)I1C2C1 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 1
- 108010022999 Serine Proteases Proteins 0.000 description 1
- 102000012479 Serine Proteases Human genes 0.000 description 1
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical group [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 1
- 125000004849 alkoxymethyl group Chemical group 0.000 description 1
- 125000005157 alkyl carboxy group Chemical group 0.000 description 1
- 125000004414 alkyl thio group Chemical group 0.000 description 1
- 125000005530 alkylenedioxy group Chemical group 0.000 description 1
- 125000004659 aryl alkyl thio group Chemical group 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 125000005619 boric acid group Chemical group 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 125000006312 cyclopentyl amino group Chemical group [H]N(*)C1([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 238000006114 decarboxylation reaction Methods 0.000 description 1
- 238000005661 deetherification reaction Methods 0.000 description 1
- 238000005695 dehalogenation reaction Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 230000001965 increasing effect Effects 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 125000004957 naphthylene group Chemical group 0.000 description 1
- 125000006501 nitrophenyl group Chemical group 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- UUEVFMOUBSLVJW-UHFFFAOYSA-N oxo-[[1-[2-[2-[2-[4-(oxoazaniumylmethylidene)pyridin-1-yl]ethoxy]ethoxy]ethyl]pyridin-4-ylidene]methyl]azanium;dibromide Chemical compound [Br-].[Br-].C1=CC(=C[NH+]=O)C=CN1CCOCCOCCN1C=CC(=C[NH+]=O)C=C1 UUEVFMOUBSLVJW-UHFFFAOYSA-N 0.000 description 1
- 125000000843 phenylene group Chemical group C1(=C(C=CC=C1)*)* 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 125000005550 pyrazinylene group Chemical group 0.000 description 1
- 125000005551 pyridylene group Chemical group 0.000 description 1
- 125000005576 pyrimidinylene group Chemical group 0.000 description 1
- 238000006268 reductive amination reaction Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 description 1
- 125000005557 thiazolylene group Chemical group 0.000 description 1
- 125000005556 thienylene group Chemical group 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 125000005951 trifluoromethanesulfonyloxy group Chemical group 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE1998104085 DE19804085A1 (de) | 1998-02-03 | 1998-02-03 | 5-Gliedrige heterocyclische kondensierte Benzoderivate, deren Herstellung und deren Verwendung als Arzneimittel |
| DE1998134325 DE19834325A1 (de) | 1998-07-30 | 1998-07-30 | 5-Gliedrige heterocyclische kondensierte Derivate, deren Herstellung und deren Verwendung als Arzneimittel |
| DE19834325.6 | 1998-07-30 | ||
| DE19804085.7 | 1998-07-30 | ||
| PCT/EP1999/000537 WO1999040072A1 (de) | 1998-02-03 | 1999-01-28 | 5-gliedrige benzokondensierte heterocyclen als antithrombotika |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2002502844A JP2002502844A (ja) | 2002-01-29 |
| JP2002502844A5 true JP2002502844A5 (enExample) | 2006-03-23 |
Family
ID=26043548
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000530502A Pending JP2002502844A (ja) | 1998-02-03 | 1999-01-28 | ５員複素環縮合ベンゾ誘導体、その調製及び医薬品としてのそれらの使用 |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP1060166A1 (enExample) |
| JP (1) | JP2002502844A (enExample) |
| AU (1) | AU2720199A (enExample) |
| CA (1) | CA2319494A1 (enExample) |
| WO (1) | WO1999040072A1 (enExample) |
Families Citing this family (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6291514B1 (en) | 1998-02-09 | 2001-09-18 | 3-Dimensional Pharmaceuticals, Inc. | Heteroaryl amidines, methylamidines and guanidines, preparation thereof, and use thereof as protease inhibitors |
| AR023510A1 (es) | 1999-04-21 | 2002-09-04 | Astrazeneca Ab | Un equipo de partes, formulacion farmaceutica y uso de un inhibidor de trombina. |
| EP1214330A1 (en) * | 1999-09-21 | 2002-06-19 | LION Bioscience AG | Benzimidazole derivatives and combinatorial libraries thereof |
| DK1220844T3 (da) * | 1999-09-24 | 2003-07-28 | Boehringer Ingelheim Pharma | Arylsulfonamid-substituerede benzimidazolderivater og deres anvendelse som tryptase-inhibitorer |
| US6407130B1 (en) | 1999-11-10 | 2002-06-18 | Boehringer Ingelheim Pharma Kg | Carboxamide-substituted benzimidazoles having tryptase-inhibiting activity |
| DE19953899A1 (de) * | 1999-11-10 | 2001-05-17 | Boehringer Ingelheim Pharma | Carboxamid-substituierte Benzimidazolderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| US6451832B2 (en) | 1999-12-23 | 2002-09-17 | Boehringer Ingelheim Pharma Kg | Benzimidazoles with antithrombotic activity |
| DE19962329A1 (de) * | 1999-12-23 | 2001-06-28 | Boehringer Ingelheim Pharma | Benzimidazole, deren Herstellung und deren Verwendung als Arzneimittel |
| US6448281B1 (en) * | 2000-07-06 | 2002-09-10 | Boehringer Ingelheim (Canada) Ltd. | Viral polymerase inhibitors |
| US6670364B2 (en) | 2001-01-31 | 2003-12-30 | Telik, Inc. | Antagonists of MCP-1 function and methods of use thereof |
| US6962926B2 (en) | 2001-01-31 | 2005-11-08 | Telik, Inc. | Antagonist of MCP-1 function, and compositions and methods of use thereof |
| US6656956B2 (en) | 2001-02-08 | 2003-12-02 | Boehringer Ingelheim Pharma Kg | Benzimidazole derivatives, processes for preparing them and their use as pharmaceutical compositions |
| DE10105628A1 (de) * | 2001-02-08 | 2002-08-22 | Boehringer Ingelheim Pharma | Benzimidazolderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| TWI245761B (en) | 2001-03-01 | 2005-12-21 | Telik Inc | Antagonists of MCP-1 function and methods of use thereof |
| TWI236474B (en) | 2001-04-03 | 2005-07-21 | Telik Inc | Antagonists of MCP-1 function and methods of use thereof |
| HUP0400467A3 (en) * | 2001-04-19 | 2012-08-28 | Eisai R & D Man Co | 2-iminopyrrolidine derivatives, pharmaceutical compositions containing them and their use |
| DE10125478A1 (de) * | 2001-05-25 | 2002-11-28 | Boehringer Ingelheim Pharma | Verwendung bicyclischer Heterocyclen zur Behandlung und Vorbeugung arterieller thrombotischer Erkrankungen |
| US7232924B2 (en) | 2001-06-11 | 2007-06-19 | Xenoport, Inc. | Methods for synthesis of acyloxyalkyl derivatives of GABA analogs |
| US6818787B2 (en) | 2001-06-11 | 2004-11-16 | Xenoport, Inc. | Prodrugs of GABA analogs, compositions and uses thereof |
| US8048917B2 (en) | 2005-04-06 | 2011-11-01 | Xenoport, Inc. | Prodrugs of GABA analogs, compositions and uses thereof |
| US7186855B2 (en) | 2001-06-11 | 2007-03-06 | Xenoport, Inc. | Prodrugs of GABA analogs, compositions and uses thereof |
| EP1569912B1 (en) | 2002-12-03 | 2015-04-29 | Pharmacyclics, Inc. | 2-(2-hydroxybiphenyl-3-yl)-1h-benzoimidazole-5-carboxamidine derivatives as factor viia inhibitors |
| AU2003215664A1 (en) * | 2002-03-21 | 2003-10-08 | Basf Aktiengesellschaft | Fungicidal triazolopyrimidines, methods for producing the same, use thereof for combating harmful fungi and agents containing said substances |
| JP4628678B2 (ja) * | 2002-03-29 | 2011-02-09 | ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド | 置換ベンズアゾールおよびＲａｆキナーゼ阻害剤としてのそれらの使用 |
| JP4334476B2 (ja) * | 2002-07-29 | 2009-09-30 | 株式会社静岡カフェイン工業所 | １，３アゾール誘導体及び同誘導体を含む血栓症治療のための医薬組成物 |
| PE20040804A1 (es) * | 2002-12-19 | 2004-12-31 | Boehringer Ingelheim Pharma | DERIVADOS DE CARBOXAMIDAS COMO INHIBIDORES DEL FACTOR Xa |
| AU2004218187C1 (en) | 2003-02-19 | 2011-04-07 | Eisai R&D Management Co., Ltd. | Methods for producing cyclic benzamidine derivatives |
| BRPI0515522A (pt) * | 2004-09-21 | 2008-07-29 | Athersys Inc | composto, composição farmacêutica. métodos de inibir a ligação de ligandos endógenos ao receptor crth-2 em uma célula, de tratar, melhorar ou prevenir um distúrbio responsivo à inibição da ligação de ligandos endógenos ao receptor crth-2 em um animal e de preparar um composto, e, kit |
| ES2318556T3 (es) * | 2004-11-02 | 2009-05-01 | Pfizer, Inc. | Derivados de sulfonil bencimidazol. |
| US7514460B2 (en) | 2004-12-22 | 2009-04-07 | 4Sc Ag | Benzazole analogues and uses thereof |
| CA2670103C (en) | 2006-12-04 | 2012-10-16 | Boehringer Ingelheim International Gmbh | Inhibitors of hiv replication |
| EP2078711A1 (en) * | 2007-12-28 | 2009-07-15 | AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.p.A. | (Aza)indole derivative substituted in position 5, pharmaceutical composition comprising it, intermediate compounds and preparation process therefor |
| MX2013001612A (es) * | 2010-08-10 | 2013-07-05 | Abbvie Inc | Moduladores de trpv3 novedosos. |
| WO2012129491A1 (en) | 2011-03-24 | 2012-09-27 | Abbott Laboratories | Trpv3 modulators |
| CA2853097A1 (en) | 2011-10-24 | 2013-05-02 | Abbvie Inc. | Novel trpv3 modulators |
| US9056874B2 (en) | 2012-05-04 | 2015-06-16 | Novartis Ag | Complement pathway modulators and uses thereof |
| DK2897939T3 (en) | 2012-09-21 | 2017-05-08 | Sanofi Sa | BENZOIMIDAZOLCARBOXYL ACID AMIDE DERIVATIVES FOR THE TREATMENT OF METABOLIC OR CARDIOVASCULAR DISEASES |
| JP6488239B2 (ja) | 2013-01-18 | 2019-03-20 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | Ｒｏｃｋ阻害剤としてのフタラジノンおよびイソキノリノン |
| JP6387391B2 (ja) | 2013-03-14 | 2018-09-05 | ノバルティス アーゲー | 眼科疾患の処置に有用な補体因子Ｂ阻害剤としての２−（１Ｈ−インドール−４−イルメチル）−３Ｈ−イミダゾ［４，５−ｂ］ピリジン−６−カルボニトリル誘導体 |
| EP3089963A1 (en) | 2013-10-30 | 2016-11-09 | Novartis AG | 2-benzyl-benzimidazole complement factor b inhibitors and uses thereof |
| US9902702B2 (en) | 2014-07-15 | 2018-02-27 | Bristol-Myers Squibb Company | Spirocycloheptanes as inhibitors of rock |
| WO2016187620A2 (en) * | 2015-05-21 | 2016-11-24 | The Regents Of The University Of California | Anti-cancer compounds |
| KR102494294B1 (ko) | 2016-06-24 | 2023-01-31 | 더 리전트 오브 더 유니버시티 오브 캘리포니아 | Parp1, pap2 및/또는 튜블린의 저해제로서 암 치료에 유용한 프탈라진 유도체 |
| WO2024243692A1 (en) * | 2023-05-30 | 2024-12-05 | Queen's University At Kingston | Cyp26b1 inhibitor compounds and methods of use thereof |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3531658A1 (de) * | 1985-09-05 | 1987-03-12 | Boehringer Mannheim Gmbh | Heterocyclisch substituierte indole, zwischenprodukte, verfahren zu ihrer herstellung und arzneimittel |
| DE3701277A1 (de) * | 1987-01-17 | 1988-07-28 | Boehringer Mannheim Gmbh | Neue tricyclische benzimidazole, verfahren zu ihrer herstellung und verwendung als arzneimittel |
| DE4129603A1 (de) * | 1991-09-06 | 1993-03-11 | Thomae Gmbh Dr K | Kondensierte 5-gliedrige heterocyclen, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel |
| ZA928276B (en) * | 1991-10-31 | 1993-05-06 | Daiichi Seiyaku Co | Aromatic amidine derivates and salts thereof. |
| DE4213919A1 (de) * | 1992-04-28 | 1993-11-04 | Thomae Gmbh Dr K | Cyclische iminoderivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel |
| US5342851A (en) * | 1992-10-07 | 1994-08-30 | Mcneil-Ppc, Inc. | Substituted thiazole derivatives useful as platelet aggregation inhibitors |
| CA2134192A1 (en) * | 1993-11-12 | 1995-05-13 | Michael L. Denney | 5, 6-bicyclic glycoprotein iib/iiia antagonists |
| PE121699A1 (es) * | 1997-02-18 | 1999-12-08 | Boehringer Ingelheim Pharma | Heterociclos biciclicos disustituidos como inhibidores de la trombina |
| DE19718181A1 (de) * | 1997-04-30 | 1998-11-05 | Boehringer Ingelheim Pharma | Disubstituierte bicyclische Heterocyclen, ihre Herstellung und ihre Verwendung als Arzneimittel |
-
1999
- 1999-01-28 EP EP99907437A patent/EP1060166A1/de not_active Withdrawn
- 1999-01-28 JP JP2000530502A patent/JP2002502844A/ja active Pending
- 1999-01-28 AU AU27201/99A patent/AU2720199A/en not_active Abandoned
- 1999-01-28 WO PCT/EP1999/000537 patent/WO1999040072A1/de not_active Ceased
- 1999-01-28 CA CA002319494A patent/CA2319494A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2002502844A5 (enExample) | ||
| US6936613B2 (en) | Benzimidazole derivatives and pharmaceutical compositions comprising these compounds | |
| US7060722B2 (en) | Proline derivatives and use thereof as drugs | |
| JP6193922B2 (ja) | ハロアルキルヘテロアリールベンズアミド化合物 | |
| HRP20120048T1 (hr) | Spojevi za i postupci moduliranja fxr | |
| JP2006501273A5 (enExample) | ||
| JP2003300959A5 (enExample) | ||
| US20190111052A1 (en) | Methods of treating a neurodegenerative disease | |
| AU2015237245A1 (en) | Potent soluble epoxide hydrolase inhibitors | |
| CN105143201A (zh) | 苄胺衍生物 | |
| CA2985366A1 (en) | Methods of treating a neurodegenerative disease | |
| JP2006524225A5 (enExample) | ||
| TW200626148A (en) | Heterocyclic derivatives and their use as therapeutic agents | |
| CA2565813A1 (en) | Substituted methyl aryl or heteroaryl amide compounds | |
| TW200640900A (en) | 1-(2h)-isoquinolone derivative | |
| TW200800938A (en) | Indole carboxylic acid derivatives exhibiting PGD2 receptor antagonism | |
| TW200504085A (en) | Derivatives of [2-(8,9-dioxo-2, 6-diazabicyclo[5.2.0]non-1(7)-en-2-yl)alkyl]phosphonic acid and methods of use thereof | |
| JP2002523511A5 (enExample) | ||
| CA2628844A1 (en) | Pyrazole derivatives and their medical use | |
| JP2014510695A5 (enExample) | ||
| KR101659982B1 (ko) | 페닐 피페라진 화합물, 이를 포함하는 약학적 조성물 및 그 용도 | |
| JP2008063256A (ja) | β‐アミノ酸誘導体 | |
| DE10229070A1 (de) | Phenylderivate 5 | |
| HUP0303038A2 (hu) | Szubsztituált azolszármazékok mint kortikotropin releasing faktor inhibitorok, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk | |
| JPWO2003022821A1 (ja) | ２０−ｈｅｔｅ産生酵素阻害作用を有するヘテロ環誘導体 |